J&J hands over $3.1M for .Baby; Pfizer announces promising Phase III data for Lyrica;

> Johnson & Johnson ($JNJ) shelled out $3.1 million in an auction for .Baby, beating out bidders such as Google ($GOOG). Story

> Pfizer ($PFE) reported promising Phase III clinical results for its nerve-pain treatment Lyrica (pregabalin). More (sub. req.)

> The FDA's Office of Prescription Drug Promotion is cracking down on one of Sunovion's print ads for seizure med Aptiom. Story (reg. req.)

> Starting in January, the Indian government will ban pharma companies from handing out freebies to doctors. More

> Apotex submitted an application to the FDA for a copycat version of Amgen's ($AMGN) $3.5 billion blockbuster Neulasta. Story (req. req.)

And Finally… The pharma industry is funneling money into veterinary education, with the world's leading animal drugmaker, Zoetis ($ZTS), awarding $3.6 million in scholarships over the past 5 years. More

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.